Research article

Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial

Edith Fleischmann¹ , Corinna Marschalek¹ , Katja Schlemitz¹ , Jarrod E Dalton^3,4 , Thomas Gruenberger² , Friedrich Herbst² , Andrea Kurz⁴ and Daniel I Sessler⁴

¹Department of Anesthesiology and Intensive Care and Pain Medicine, Medical University Vienna, Vienna, Austria

²Department of General Surgery, Medical University Vienna, Vienna, Austria

³Department of Quantitative Health Sciences, The Cleveland Clinic, Cleveland, Ohio, USA

⁴Outcomes Research, The Cleveland Clinic, Cleveland, Ohio, USA

author email corresponding author email

BMC Anesthesiology 2009, 9:1doi:10.1186/1471-2253-9-1

Published:	3 February 2009

Abstract

Background

Even the best cancer surgery is usually associated with minimal residual disease. Whether these remaining malignant cells develop into clinical recurrence is at least partially determined by adequacy of host defense, especially natural killer cell function. Anesthetics impair immune defenses to varying degrees, but nitrous oxide appears to be especially problematic. We therefore tested the hypothesis that colorectal-cancer recurrence risk is augmented by nitrous oxide administration during colorectal surgery.

Methods

We conducted a 4- to 8-year follow-up of 204 patients with colorectal cancer who were randomly assigned to 65% nitrous oxide (n = 97) or nitrogen (n = 107), balanced with isoflurane and remifentanil. The primary outcome was the time to cancer recurrence. Our primary analysis was a multivariable Cox-proportional-hazards regression model that included relevant baseline variables. In addition to treatment group, the model considered patient age, tumor grade, dissemination, adjacent organ invasion, vessel invasion, and the number of nodes involved. The study had 80% power to detect a 56% or greater reduction in recurrence rates (i.e., hazard ratio of 0.44 or less) at the 0.05 significance level.

Results

After adjusting for significant baseline covariables, risk of recurrence did not differ significantly for nitrous oxide and nitrogen, with a hazard ratio estimate (95% CI) of 1.10 (0.66, 1.83), P = 0.72. No two-way interactions with the treatment were statistically significant.

Conclusion

Colorectal-cancer recurrence risks were not greatly different in patients who were randomly assigned to 65% nitrous oxide or nitrogen during surgery. Our results may not support avoiding nitrous oxide use to prevent recurrence of colorectal cancer.

Implications Statement

The risk of colorectal cancer recurrence was similar in patients who were randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.

Trial Registration

Current Controlled Clinical Trials NCT00781352 http://www.clinicaltrials.gov webcite